Ovarian Hyperstimulation Syndrome Clinical Trial
Official title:
The Randomized Clinical Trials of Letrozole Administration During Luteal Phase in Patients Who Have the Risk of Ovarian Hyperstimulation Syndrome
To investigate the effect of letrozole in patients who have high risk of ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval, the incidence of OHSS were calculated between letrozole group and supporting treatment group.
1. Object: Infertility patients who frozen all embryos due to the risk of OHSS were randomized allocated to letrozole or polygeline injection group. Inclusion criteria meet one of the following conditions: (1) oocyte is more than or equal to 20; (2) human chorionic gonadotropin (hCG) injection on serum estradiol levels greater than or equal to 5000 pmol/L; (3) on the day of oocyte unilateral or bilateral ovarian diameter greater than or equal to 10 cm (4) follicle puncture is larger than or equal to number 20. After the informed consent was signed, letrozole or polygeline injection was randomized allocated after oocyte retrieval. OHSS was determined according to Golan diagnosis standards. 2. Clinical data: Including age, infertility duration, body mass index (BMI), basic follicle-stimulating hormone (FSH) and luteinizing hormone (LH), antral follicle number (AFC), Gn dosage, estradiol level on hCG injection day, the number of oocytes, the number of embryos, early onset OHSS incidence, and the existence of ascites. 3. Reproductive hormone levels: 1, 4, 7, days after taken letrozole, and the supernatant was collected for serum reproductive hormone test. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00617864 -
The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome
|
N/A | |
| Withdrawn |
NCT01979341 -
The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes
|
N/A | |
| Completed |
NCT01427335 -
Calcium for Prevention of Ovarian Hyperstimulation Syndrome
|
Phase 3 | |
| Completed |
NCT01014104 -
Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00119925 -
'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"
|
N/A | |
| Completed |
NCT06333691 -
Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin
|
N/A | |
| Terminated |
NCT01714648 -
Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?
|
Phase 4 | |
| Completed |
NCT01500863 -
Endometrial Receptivity After GnRH Agonist Triggering
|
Phase 4 | |
| Recruiting |
NCT00417144 -
Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients
|
Phase 4 | |
| Completed |
NCT03876145 -
The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome
|
N/A | |
| Completed |
NCT05588635 -
Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
|
||
| Not yet recruiting |
NCT02392520 -
Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)
|
N/A | |
| Completed |
NCT00835523 -
Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist
|
N/A | |
| Completed |
NCT00665041 -
Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05638529 -
Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT03071172 -
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
|
Phase 3 | |
| Recruiting |
NCT02084940 -
Long Acting GnRH Antagonist in PCOS Women Undergoing IVF
|
N/A | |
| Completed |
NCT01815138 -
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
|
Phase 4 | |
| Completed |
NCT00867659 -
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
|
N/A | |
| Completed |
NCT01569256 -
Ovarian Hyperstimulation Syndrome and Cabergoline
|
N/A |